kymriah
(Tisagenlecleucel)Novartis Pharmaceuticals Corporation
Usage: Kymriah is a CD19-directed CAR-T cell therapy for patients up to 25 with refractory or relapsed B-cell precursor ALL; adults with relapsed/refractory large B-cell lymphoma after 2+ prior therapies; and adults with relapsed/refractory follicular lymphoma after 2+ prior therapies (accelerated approval).